COYA Stock Forecast: Coya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.95
−1.01% on the day

The median 12-month analyst price target for Coya Therapeutics, Inc. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$69.2M
Ticker Nerd rank
28/ 100
Median analyst target
$16
Analysts covering
7
Revenue$244K+49.0% y/y
Operating income−$7.0M
Net income−$6.6M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
−29.9%
YTD
−49.1%
1Y
−50.7%
From 52W high
−54.7%
From 52W low
+5.0%
$2.81
$6.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Coya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
62
Accruals
48
Value
44
Growth
40
Quality
39
Revisions
33
Issuance
29
Momentum
26

Volatility (62): The share price has been relatively steady.

Momentum (26): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26COYAHigh $18Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$12
Low
$16
Median
$18
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2026HC Wainwright & Co.ReiteratesBuy$18
15 Sept 2026BTIGReiteratesBuy$16
24 Aug 2026Roth CapitalReiteratesBuy$12
12 Aug 2026Chardan CapitalMaintainsBuy$14
12 June 2026Chardan CapitalMaintainsBuy$14
5 June 2026Roth CapitalInitiatesBuy$12
10 Apr 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
18 Feb 2026D. Boral CapitalMaintainsBuy—
2 Feb 2026HC Wainwright & Co.ReiteratesBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026Chardan CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
23 Dec 2025D. Boral CapitalMaintainsBuy—
9 Dec 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COYA.

Market Radar

This page is one stock. Monday covers all of them.

COYA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COYA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Coya Therapeutics, Inc. returned −50.7% against +6.9% for the S&P 500, dividends included.

COYA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26COYAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
14.8×

Cheaper than 9% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−99.2%

Higher than 13% of US stocks

Return on assets
−52.3%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coya Therapeutics, Inc. has a market value of $69.2M and an enterprise value of $33.4M.

  • Revenue in the twelve months to 30 June 2026: $8.0M. The latest quarter grew 49.0% year on year.

  • Net income over the same four quarters: −$21.7M, a −270.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$16.6M.

  • Shares outstanding: 23.5M.

  • Coya Therapeutics, Inc. employs 8 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

COYA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COYACoya Therapeutics, Inc.$69.2M28
RANIRani Therapeutics Holdings, Inc.$69.7M58
MAIAMAIA Biotechnology, Inc.$67.3M40
PLYXPolaryx Therapeutics, Inc.$66.3M11
PMVPPMV Pharmaceuticals, Inc.$66.1M56
CRDFCardiff Oncology, Inc.$65.7M48
CINGCingulate, Inc.$65.6M25

Take a look at COYA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Coya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about COYA

What is the COYA stock price forecast for 2026-2027?

The median 12-month analyst price target for Coya Therapeutics, Inc. is $16, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COYA stock a buy right now?

Of the 7 analysts covering Coya Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coya Therapeutics, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COYA?

As at 21 Nov 2026, Coya Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (62 of 100).

Will COYA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $16, and Ticker Nerd's factor model ranks Coya Therapeutics, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COYA stock forecast for 2030?

No analyst covering Coya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.

How has COYA stock performed over the past year?

Coya Therapeutics, Inc. returned -50.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coya Therapeutics, Inc. do?

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Company

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.

CEO Dr. Arun Swaminathan Ph.D. · 8 employees · United States · https://www.coyatherapeutics.com